| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2016: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2015: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Outline of Final Research Achievements |
Identifying useful biomarkers were essential to select optimal therapeutic strategies for cancer. Quantitative real-time PCR analysis revealed higher expression of EZH2 in clinical gastric cancer tissues than in corresponding non-neoplastic tissues, and we comfirmed that a wide range of cancers also overexpress EZH2, using cDNA microarray analysis. Immunohistochemical analysis showed positive staining (>50%) for EZH2 in 77 of 97 cases of gastric cancer. We could not find elevated expression of EZH2 to be associated with poor prognosis for patients with gastric cancer (P=0.670). Our study has demonstrated that combination of s-p53Ab and other tumor markers can serve as a useful biomarker set of gastrointestinal cancer and should be incorporated into traditional clinical and pathologic variables to complement outcome prediction of gastrointestinal cancer patients after treatment.
|
